for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,409.20GBp

Change

1.00(+0.07%)

Volume

601,192

Today's Range

1,403.80

 - 

1,411.80

52 Week Range

1,190.80

 - 

1,528.80

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Latest Developments

GSK Says 'Far Advanced' With Plan For Separation Of Consumer Unit

Oct 12 (Reuters) - GlaxoSmithKline PLC <GSK.L>::GSK SAYS 'GSK IS FAR ADVANCED WITH ITS PLAN FOR THE SEPARATION OF CONSUMER HEALTHCARE'.GSK SAYS 'PLANS TO DELIVER THE DEMERGER ARE WELL-ADVANCED AND WE ARE FIRMLY ON TRACK TO MEET OUR MID-2022 TIMELINE'.GSK SAYS FEEDBACK FROM SHAREHOLDERS IS THAT THEY ARE VERY KEEN TO OWN NEW CONSUMER HEALTHCARE COMPANY AS LISTED ENTITY.GSK SAYS WILL FULFIL FIDUCIARY DUTIES TO EVALUATE ANY ALTERNATIVE OPTIONS FOR CONSUMER HEALTHCARE.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

GlaxoSmithKline's Consumer Unit Is Drawing Interest From Private Equity Firms - Bloomberg News

Oct 12 (Reuters) - :PRIVATE EQUITY FIRMS CIRCLE GLAXOSMITHKLINE’S $54 BILLION CONSUMER ARM - BLOOMBERG NEWS.POTENTIAL SUITORS FOR GLAXOSMITHKLINE’S $54 BILLION CONSUMER ARM INCLUDE ADVENT, CVC, KKR - BLOOMBERG NEWS.BLACKSTONE INC, CARLYLE GROUP, PERMIRA ALSO AMONG POTENTIAL SUITORS EVALUATING GSK'S CONSUMER ARM - BLOOMBERG NEWS.Further company coverage: BX.N. ((Reuters.Briefs@thomsonreuters.com;)).

Novartis Unit Sandoz Completes Acquisition Of GSK's Cephalosporin Business

Oct 11 (Reuters) - NOVARTIS AG <NOVN.S>::SANDOZ COMPLETES ACQUISITION OF GSK’S CEPHALOSPORIN BUSINESS, REINFORCING LEADING GLOBAL POSITION IN ANTIBIOTICS.

FDA Says Distribution Of Authorized Sotrovimab Will Be Controlled By U.S. Government

Oct 8 (Reuters) - U.S. FDA::FDA SAYS IS REISSUING MAY 26, 2021 LETTER IN ITS ENTIRETY, TO REFLECT THAT DISTRIBUTION OF AUTHORIZED SOTROVIMAB WILL BE CONTROLLED BY U.S. GOVERNMENT.

Medicago, GSK To Launch Trials Of COVID-19 Vaccine Candidate In Japan

Oct 1 (Reuters) - GlaxoSmithKline <GSK.L> and Medicago::MEDICAGO TO LAUNCH CLINICAL TRIALS FOR COVID-19 VACCINE CANDIDATE WITH GSK'S PANDEMIC ADJUVANT IN JAPAN.MEDICAGO’S COVID-19 VACCINE CANDIDATE HAS NOW COMPLETED ENROLLMENT OF ITS PHASE 2/3 CLINICAL TRIALS.STUDY, WITH FINAL DATA FROM GLOBAL PHASE 2/3 STUDY OF VACCINE CANDIDATE, TO BE USED TO SUPPORT APPLICATION FOR APPROVAL IN JAPAN BY MARCH OF 2022..Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

Merck Announces Mutual Decision To End Bintrafusp Alfa Agreement With GSK

Sept 30 (Reuters) - MERCK KGAA <MRCG.DE>::MERCK ANNOUNCES MUTUAL DECISION TO END BINTRAFUSP ALFA AGREEMENT WITH GSK.EFFECTIVE SEPTEMBER 30, 2021.DECISION IS BASED ON CLINICAL TRIAL DATA GENERATED TO DATE, MOST NOTABLY PREVIOUSLY REPORTED RESULTS FROM INTR@PID LUNG 037 STUDY, WHICH DID NOT REPLICATE ENCOURAGING DATA OBSERVED IN EARLIER STUDIES.NO MILESTONE PAYMENTS WERE MADE BY GSK AND NO FUTURE MILESTONE OBLIGATIONS REMAIN.Further company coverage: MRCG.DE. (Gdansk Newsroom). ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;)).

GSK's ViiV Healthcare To Develop Next-Gen HIV Treatments With Shionogi

Sept 28 (Reuters) - GlaxoSmithKline PLC <GSK.L>::VIIV HEALTHCARE ANNOUNCES EXCLUSIVE LICENSE AGREEMENT WITH SHIONOGI TO DEVELOP THIRD-GENERATION HIV INTEGRASE INHIBITOR WITH POTENTIAL FOR ULTRA LONG-ACTING DOSING INTERVALS.GSK - S-365598 AIMS TO BUILD ON SUCCESS OF DOLUTEGRAVIR AND CABOTEGRAVIR WITH POTENTIAL TO ANCHOR NEXT GENERATION OF LONG-ACTING THERAPIES FOR HIV.GSK - VIIV WILL MAKE UPFRONT PAYMENT OF £20 MILLION TO SHIONOGI, £15 MILLION PAYMENT FOR ACHIEVEMENT OF CLINICAL DEVELOPMENT MILESTONE, ROYALTIES ON NET SALES.GSK - VIIV HEALTHCARE AND SHIONOGI INTEND TO INITIATE FIRST TIME IN HUMAN STUDIES WITH S-365598 BY 2023..Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

Sanofi Announces Positive Phase 1/2 Interim Results For Its First mRNA-Based Vaccine Candidate

Sept 28 (Reuters) - Sanofi <SASY.PA>::SANOFI ANNOUNCES POSITIVE PHASE 1/2 STUDY INTERIM RESULTS FOR ITS FIRST MRNA-BASED VACCINE CANDIDATE.HIGH SEROCONVERSION ACROSS THREE DOSAGES TESTED AND COMPARABLE TOLERABILITY TO OTHER UNMODIFIED MRNA COVID-19 VACCINESF&B.NOW ACCELERATING TRANSFORMATION OF ACQUIRED PLATFORM TO MODIFIED MRNA AND TARGETING A MODIFIED QUADRIVALENT FLU MRNA VACCINE IN CLINIC IN 2022.ANNOUNCES POSITIVE PHASE 1/2 STUDY INTERIM RESULTS FOR ITS FIRST MRNA-BASED VACCINE CANDIDATE.INITIAL DATA FROM PHASE 1/2 SHOWED NEUTRALIZING ANTIBODY SEROCONVERSION (DEFINED AS 4-FOLD INCREASE VERSUS BASELINE) IN 91% TO 100% OF STUDY PARTICIPANTS, TWO WEEKS AFTER A SECOND INJECTION, ACROSS ALL 3 DOSAGES TESTED.NO SAFETY CONCERN HAS BEEN OBSERVED AND TOLERABILITY PROFILE IS COMPARABLE TO THAT OF OTHER UNMODIFIED MRNA COVID-19 VACCINES.FURTHER DATA FROM THIS FIRST STUDY OF SANOFI'S MRNA PLATFORM WILL BE PRESENTED AT A LATER DATE.TARGETING 2022 INITIATION OF ITS CLINICAL STUDIES FOR AN INFLUENZA VACCINE WITH MODIFIED MRNA, SANOFI LAUNCHED A PHASE 1 CLINICAL TRIAL IN JUNE 2021.CONTINUES ITS EFFORTS IN FIGHT AGAINST COVID-19 PANDEMIC WITH ITS ADJUVANTED RECOMBINANT PROTEIN CANDIDATE VACCINE.EVALUATING AN MRNA-BASED INVESTIGATIONAL VACCINE AGAINST SEASONAL INFLUENZA.TRIAL WILL EVALUATE SAFETY AND IMMUNOGENICITY OF A MONOVALENT FLU VACCINE CANDIDATE CODING FOR HEMAGGLUTININ PROTEIN OF A/H3N2 STRAIN OF INFLUENZA VIRUS ACROSS TWO FORMULATIONS (MRT5400 AND MRT5401) WITH DIFFERENT LIPID NANOPARTICLES.

Bluebell Capital Says Believes GSK Should Address Leadership For “New GSK” - Letter

Sept 22 (Reuters) - BLUEBELL CAPITAL::BLUEBELL CAPITAL SENDS LETTER TO CHAIRMAN OF GSK.BLUEBELL CAPITAL SAYS BELIEVES GSK SHOULD ADDRESS IN THE SHORT TERM, THE LEADERSHIP FOR “NEW GSK”.BLUEBELL CAPITAL: ASK GSK BOARD TO ACCELERATE FURTHER APPOINTMENTS TO GSK BOARD WITH OBJECTIVE TO INCREASE BIOPHARMACEUTICALS, SCIENTIFIC EXPERIENCE.BLUEBELL CAPITAL: ASKS GSK TO LAUNCH IMMEDIATELY AFTERWARDS THOROUGH, ROBUST PROCESS TO IDENTIFY BEST(INTERNAL OR EXTERNAL) CANDIDATE TO LEAD NEW GSK.BLUEBELL CAPITAL: ASKS GSK TO TAKE A PROACTIVE APPROACH TO CONSIDER AVAILABLE ALTERNATIVE TRANSACTIONS TO DEMERGER OF CONSUMER HEALTHCARE.BLUEBELL CAPITAL SAYS VIEWS GSK VACCINE FRANCHISE AS GENERALLY UNDERVALUED BY MARKET - LETTER.BLUEBELL WRITES TO GSK IN RELATION TO INVESTMENT AND/OR ECONOMIC INTEREST IN GSK COMMON EQUITY SHARES BY BLUEBELL ACTIVE EQUITY MASTER FUND ICAV.BLUEBELL CAPITAL SAYS BELIEVES GSK'S EMMA WALMSLEY WOULD HAVE BEEN A VERY CREDIBLE CANDIDATE FOR THE POSITION OF CEO AT CONSUMER HEALTHCARE.Further company coverage: GSK.L. ((Reuters.Briefs@thomsonreuters.com;)).

GSK Announces £50m Investment In Renewable Energy And Carbon Reduction

Sept 20 (Reuters) - GlaxoSmithKline PLC <GSK.L>::PRESS RELEASE: GSK ANNOUNCES MAJOR RENEWABLE ENERGY INVESTMENT AND LOW CARBON INHALER PROGRAMME ALONGSIDE LIFE SCIENCES SECTOR RACE TO ZERO ‘BREAKTHROUGH’ AT NYC CLIMATE WEEK.GSK - ANNOUNCES £50M INVESTMENT IN RENEWABLE ENERGY AND CARBON REDUCTION.GSK - ALSO ANNOUNCED TO REDUCE GREENHOUSE GAS EMISSIONS FROM RESCUE METERED DOSE INHALERS, RESPONSIBLE FOR 45% OF GSK'S CARBON EMISSIONS.GSK - NEW PROGRAMMES SUPPORT DELIVERY OF GSK GOALS OF ACHIEVING NET ZERO IMPACT ON CLIMATE AND NET POSITIVE IMPACT ON NATURE BY 2030.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up